SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism
Aims/hypothesis Congenital hyperinsulinism caused by mutations in the $ K_{ATP} $-channel-encoding genes ($ K_{ATP} $HI) is a potentially life-threatening disorder of the pancreatic beta cells. No optimal medical treatment is available for patients with diazoxide-unresponsive diffuse $ K_{ATP} $HI. Therefore, we aimed to create a model of $ K_{ATP} $HI using patient induced pluripotent stem cell (iPSC)-derived islets. Methods We derived iPSCs from a patient carrying a homozygous ABCC8V187D mutation, which inactivates the sulfonylurea receptor 1 (SUR1) subunit of the $ K_{ATP} $-channel. CRISPR-Cas9 mutation-corrected iPSCs were used as controls. Both were differentiated to stem cell-derived islet-like clusters (SC-islets) and implanted into NOD-SCID gamma mice. Results SUR1-mutant and -corrected iPSC lines both differentiated towards the endocrine lineage, but SUR1-mutant stem cells generated 32% more beta-like cells (SC-beta cells) (64.6% vs 49.0%, p = 0.02) and 26% fewer alpha-like cells (16.1% vs 21.8% p = 0.01). SUR1-mutant SC-beta cells were 61% more proliferative (1.23% vs 0.76%, p = 0.006), and this phenotype could be induced in SUR1-corrected cells with pharmacological $ K_{ATP} $-channel inactivation. The SUR1-mutant SC-islets secreted 3.2-fold more insulin in low glucose conditions (0.0174% vs 0.0054%/min, p = 0.0021) and did not respond to $ K_{ATP} $-channel-acting drugs in vitro. Mice carrying grafts of SUR1-mutant SC-islets presented with 38% lower fasting blood glucose (4.8 vs 7.7 mmol/l, p = 0.009) and their grafts failed to efficiently shut down insulin secretion during induced hypoglycaemia. Explanted SUR1-mutant grafts displayed an increase in SC-beta cell proportion and SC-beta cell nucleomegaly, which was independent of proliferation. Conclusions/interpretation We have created a model recapitulating the known pathophysiology of $ K_{ATP} $HI both in vitro and in vivo. We have also identified a novel role for $ K_{ATP} $-channel activity during human islet development. This model will enable further studies for the improved understanding and clinical management of $ K_{ATP} $HI without the need for primary patient tissue. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Diabetologia - 64(2021), 3 vom: 06. Jan., Seite 630-640 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lithovius, Väinö [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
-channel |
| doi: |
10.1007/s00125-020-05346-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043021980 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043021980 | ||
| 003 | DE-627 | ||
| 005 | 20230519155619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210206s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00125-020-05346-7 |2 doi | |
| 035 | |a (DE-627)SPR043021980 | ||
| 035 | |a (DE-599)SPRs00125-020-05346-7-e | ||
| 035 | |a (SPR)s00125-020-05346-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.89 |2 bkl | ||
| 100 | 1 | |a Lithovius, Väinö |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aims/hypothesis Congenital hyperinsulinism caused by mutations in the $ K_{ATP} $-channel-encoding genes ($ K_{ATP} $HI) is a potentially life-threatening disorder of the pancreatic beta cells. No optimal medical treatment is available for patients with diazoxide-unresponsive diffuse $ K_{ATP} $HI. Therefore, we aimed to create a model of $ K_{ATP} $HI using patient induced pluripotent stem cell (iPSC)-derived islets. Methods We derived iPSCs from a patient carrying a homozygous ABCC8V187D mutation, which inactivates the sulfonylurea receptor 1 (SUR1) subunit of the $ K_{ATP} $-channel. CRISPR-Cas9 mutation-corrected iPSCs were used as controls. Both were differentiated to stem cell-derived islet-like clusters (SC-islets) and implanted into NOD-SCID gamma mice. Results SUR1-mutant and -corrected iPSC lines both differentiated towards the endocrine lineage, but SUR1-mutant stem cells generated 32% more beta-like cells (SC-beta cells) (64.6% vs 49.0%, p = 0.02) and 26% fewer alpha-like cells (16.1% vs 21.8% p = 0.01). SUR1-mutant SC-beta cells were 61% more proliferative (1.23% vs 0.76%, p = 0.006), and this phenotype could be induced in SUR1-corrected cells with pharmacological $ K_{ATP} $-channel inactivation. The SUR1-mutant SC-islets secreted 3.2-fold more insulin in low glucose conditions (0.0174% vs 0.0054%/min, p = 0.0021) and did not respond to $ K_{ATP} $-channel-acting drugs in vitro. Mice carrying grafts of SUR1-mutant SC-islets presented with 38% lower fasting blood glucose (4.8 vs 7.7 mmol/l, p = 0.009) and their grafts failed to efficiently shut down insulin secretion during induced hypoglycaemia. Explanted SUR1-mutant grafts displayed an increase in SC-beta cell proportion and SC-beta cell nucleomegaly, which was independent of proliferation. Conclusions/interpretation We have created a model recapitulating the known pathophysiology of $ K_{ATP} $HI both in vitro and in vivo. We have also identified a novel role for $ K_{ATP} $-channel activity during human islet development. This model will enable further studies for the improved understanding and clinical management of $ K_{ATP} $HI without the need for primary patient tissue. Graphical abstract | ||
| 650 | 4 | |a Beta cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Congenital hyperinsulinism |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Disease modelling |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Induced pluripotent stem cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a K |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a -channel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pancreatic islet development |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Stem cell-derived islets |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Saarimäki-Vire, Jonna |e verfasserin |4 aut | |
| 700 | 1 | |a Balboa, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Hazem |e verfasserin |4 aut | |
| 700 | 1 | |a Montaser, Hossam |e verfasserin |4 aut | |
| 700 | 1 | |a Barsby, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Otonkoski, Timo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetologia |d Berlin : Springer, 1965 |g 64(2021), 3 vom: 06. Jan., Seite 630-640 |w (DE-627)SPR000960098 |w (DE-600)1458993-X |x 1432-0428 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2021 |g number:3 |g day:06 |g month:01 |g pages:630-640 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00125-020-05346-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.89 |q ASE |
| 951 | |a AR | ||
| 952 | |d 64 |j 2021 |e 3 |b 06 |c 01 |h 630-640 | ||